Explore
Treatment Strategies and Survival Outcomes in Breast Cancer
Kwok-Leung Cheung
2020
0 Ungluers have
Faved this Work
Login to Fave
Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 310 times via unglue.it ebook links.
- 278 - pdf (CC BY-NC-ND) at Unglue.it.
Keywords
- abemaciclib
- advanced breast cancer
- anthracycline resistance
- antihormone therapy
- APOBEC3B
- aromatase inhibitors
- ATM
- basal-like breast cancer
- biomarker
- BRCA
- Breast cancer
- breast cancer survivors
- breast-conserving therapy
- cancer treatment
- cell-free DNA
- CHEK2
- chemotherapy
- circulating tumor cells
- cMet
- colorectal cancer
- comparative effectiveness
- contralateral breast cancer
- contralateral prophylactic mastectomy
- cyclin E
- disease-free survival
- ductal carcinoma in situ
- Endocrine therapy
- ERCC1
- exercise characteristics
- family history
- fulvestrant
- Gene expression
- geriatric oncology
- HDAC5 inhibitors
- HER2 c-erbB2
- HER2/neu
- histone deacetylase
- incidence
- infiltrating breast cancer
- invasive breast cancer
- Lactate dehydrogenase
- lapatinib
- LDH
- Liquid Biopsy
- LKB1
- LMK-235
- lymph-node ratio
- mammography screening
- mastectomy
- metastatic
- metastatic breast cancer
- metformin
- monitoring metastatic breast cancer
- mutation carriers
- n/a
- NCDB
- next-generation sequencing
- older patients
- Older women
- outcome
- overdiagnosis
- PALB2
- palbociclib
- pertuzumab
- physical activity
- physical function
- PIK3CA
- prognosis
- Radiotherapy
- relative survival
- ribociclib
- SEER
- serum biomarker
- social well-being
- Src kinase
- stage IV
- Survival
- T-DM1
- taxane sensitivity
- trastuzumab
- tumor biology
- Young women
- zero-inflated Poisson regression model
Editions
